Observational Study of Long-Term Outcomes After Transcatheter Mitral and Tricuspid Valve Repair in Munich

What this Trial Is About

This research aims to observe and collect data on patients undergoing transcatheter mitral or tricuspid valve therapy at a single center in Germany. It focuses on long-term outcomes, particularly mortality over a 5-year period, for individuals with mitral valve regurgitation, mitral valve stenosis, or tricuspid valve regurgitation. The study is observational, meaning it monitors patients receiving care without assigning specific treatments. Participants receive edge-to-edge valve repair as part of their transcatheter valve therapy, which is determined by a heart-team decision to be the best option for their condition. This device-based treatment will be tracked over time as part of the registry. The study started in September 2020 and will continue through January 2031, allowing for long-term follow-up. During the study, researchers will monitor patients health and survival for up to five years after their valve therapy. Data collected will include mortality outcomes and other health information, without altering standard care. Participants provide informed consent and will be followed through regular medical assessments to contribute to understanding the therapys long-term effects.

The Prospecive OBSERVational Munich Interventional MITRAl-Valve Registry